Report from the Bone Marrow Transplant Survivor Study
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Lymphoma and Multiple Myeloma Center
The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J. -
Case-Scenario-10-FINAL.Pdf
Case scenario 10 – Magdalena Part 1 • Magdalena is 26 years old. She is 13 weeks pregnant and had a high chance combined test result of 1 in 140 for trisomy 13 with an NT measurement of 2.4mm. • After a lengthy discussion about her options, she decided to have NIPT. • The results reported a greater than 60% chance of the baby having Patau’s syndrome. She decided to have an invasive test. A CVS was performed. Would you have offered a CVS to this patient? a) No - she should be offered an amniocentesis only, due to the chance of placental factors affecting a result. b) Yes - the patient should be informed of risks and benefits of both CVS and amniocentesis. Answer b) Yes - the patient should be informed of the risks and benefits of a CVS and amniocentesis. Additional note A patient/couple should be informed of the options of both forms of diagnostic procedures. They should be informed of the benefits and limitations of each test, this should include timing of testing, possible results and risks of miscarriage. This discussion should also include the couples ethical, religious, social and individual beliefs. Name the type of mosaicism that can cause a false-positive result with NIPT. a) Feto-placental mosaicism b) Placental mosaicism c) Fetal mosaicism Answer b) Placental mosaicism Additional note There is a discrepancy of the cell line in the placenta and baby. The abnormal cell lines are seen in the placenta and not on the fetus. There is a small chance that a 'high chance report is caused by 'placental mosaicism', therefore a CVS may also report 'mosaicism’. -
Survivors of Acute Leukemia Are Less Likely to Have Liveborn Infants Than Are Their
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS PROPOSAL STUDY TITLE: Fertility Rates in Long-Term Survivors of Acute Lymphoblastic Leukemia WORKING GROUP AND INVESTIGATORS: Name Telephone Number E-mail Daniel M. Green, M.D. 901-595-5915 [email protected] Vikki Nolan, Ph.D. 901-595-6078 [email protected] Liang Zhu, Ph.D. 901-595-5240 [email protected] Marilyn Stovall, Ph.D. 713-792-3240 [email protected] Sarah Donaldson, M.D. 650-723-6195 [email protected] Les Robison, Ph.D. 901-595-5817 [email protected] Chuck Sklar, M.D. 212-717-3239 [email protected] BACKGROUND AND RATIONALE: Survivors of acute leukemia are less likely to have liveborn infants than are their female siblings (relative risk (RR) =0.63, 95% confidence interval (CI) 0.52 to 0.76). The risk of miscarriage was increased among Childhood Cancer Survivor Study (CCSS) female participants who received craniospinal (RR=2.22, 95% CI 1.36 to 3.64) or cranial irradiation (RR=1.40, 95% CI 1.02 to 1.94). The risk of miscarriage was increased in survivors of acute lymphoblastic leukemia (ALL) (RR=1.60, 95% CI 0.85 to 3.00) and central nervous system tumors (RR=1.33, 95% CI 0.61 to 2.93) although neither risk achieved statistical significance 1. Winther et al. reported that the risk of spontaneous 2 abortion was not increased in survivors of leukemia compared to their sisters (proportion ratio (PR) 1.2, 95% CI 0.7 to 2.0). However those female survivors who received low doses of radiation to the uterus and ovaries, but high doses of radiation to the pituitary had an increased risk of spontaneous abortion (PR 1.8, 95% CI 1.1 to 3.0). -
Role of Maternal Age and Pregnancy History in Risk of Miscarriage
RESEARCH Role of maternal age and pregnancy history in risk of BMJ: first published as 10.1136/bmj.l869 on 20 March 2019. Downloaded from miscarriage: prospective register based study Maria C Magnus,1,2,3 Allen J Wilcox,1,4 Nils-Halvdan Morken,1,5,6 Clarice R Weinberg,7 Siri E Håberg1 1Centre for Fertility and Health, ABSTRACT Miscarriage and other pregnancy complications might Norwegian Institute of Public OBJECTIVES share underlying causes, which could be biological Health, PO Box 222 Skøyen, To estimate the burden of miscarriage in the conditions or unmeasured common risk factors. N-0213 Oslo, Norway Norwegian population and to evaluate the 2MRC Integrative Epidemiology associations with maternal age and pregnancy history. Unit at the University of Bristol, Introduction Bristol, UK DESIGN 3 Miscarriage is a common outcome of pregnancy, Department of Population Prospective register based study. Health Sciences, Bristol Medical with most studies reporting 12% to 15% loss among School, Bristol, UK SETTING recognised pregnancies by 20 weeks of gestation.1-4 4Epidemiology Branch, National Medical Birth Register of Norway, the Norwegian Quantifying the full burden of miscarriage is Institute of Environmental Patient Register, and the induced abortion register. challenging because rates of pregnancy loss are Health Sciences, Durham, NC, USA PARTICIPANTS high around the time that pregnancies are clinically 5Department of Clinical Science, All Norwegian women that were pregnant between recognised. As a result, the total rate of recognised University of Bergen, Bergen, 2009-13. loss is sensitive to how early women recognise their Norway pregnancies. There are also differences across countries 6 MAIN OUTCOME MEASURE Department of Obstetrics and studies in distinguishing between miscarriage and and Gynecology, Haukeland Risk of miscarriage according to the woman’s age and University Hospital, Bergen, pregnancy history estimated by logistic regression. -
Therapeutic Effect and Mechanism of Ibrutinib Combined with Dexametha- Sone on Multiple Myeloma
ORIGINAL ARTICLES Hematology Department of The Second Hospital1, Cheeloo College of Medicine, Shandong University; Department of Hematology of Jining No. 1 People’s Hospital2; Institute of Biotherapy for Hematological Malignancies of Shandong University3; Shandong University-Karolinska Institute Collaborative Laboratory for Stem Cell Research4; Hematology Department of Linyi Central Hospital5; Hematology Department of Binzhou Medical University Hospital6; Institute of Medical Sciences, The Second Hospital, Cheeloo College of Medicine, Shandong University7, Jinan, Shandong, China Therapeutic effect and mechanism of ibrutinib combined with dexametha- sone on multiple myeloma SHENGLI LI1,2, LIKUN SUN1,3,4, QIAN ZHOU1,5, SHUO LI1,6, XIAOLI LIU1,3,4, JUAN XIAO1,3,4, YAQI XU1,3,4, FANG WANG7, YANG JIANG1,3,4,*, CHENGYUN ZHENG1,3,4 Received November 14, 2020, accepted December 2020 *Correspondence author: Yang Jiang, Hematology Department, the Second Hospital of Shandong University, 247th of Beiyuan Rd., Jinan, Shandong, China [email protected] Pharmazie 76: 92-96 (2021) doi: 10.1691/ph.2021.0917 Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase and has proven to be an effective agent for B-cell-mediated hematological malignancies, including multiple myeloma (MM). Several clinical trials of ibrutinib treatment combined with dexamethasone (DXMS) for relapsed MM have demonstrated high response rates, however, the mechanism still remains unclear. In this study, we explored the therapeutic effect and mechanism of ibrutinib combined with DXMS on MM in vitro and vivo. The apoptosis of MM cell lines and mononuclear cells from MM patients’ bone marrow induced by ibrutinib combined with DXMS was detected by flow cytometry and the expression of apoptosis-related proteins were detected by Western blot. -
Practice Guidelines for Molecular Diagnosis of Fragile X Syndrome
Practice Guidelines for Molecular Diagnosis of Fragile X Syndrome Prepared and edited by James Macpherson 1 and Abid Sharif 2 following a CMGS Workshop held on 10 th July 2012. 1. Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, Wiltshire, SP2 8BJ, U.K. 2. East Midlands Regional Molecular Genetics Service, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, U.K. Guidelines updated by the Association for Clinical Genetic Science (formally Clinical Molecular Genetics Society and Association of Clinical Cytogenetics) approved November 2014. 1. NOMENCLATURE and GENE IDs OMIM Condition Gene name Gene map locus 309550 Fragile X Syndrome FMR1 Xq27.3 309548 FRAXE FMR2 Xq28 2. DESCRIPTION OF DISEASE 2.1 Fragile X Syndrome Fragile X Syndrome is thought to be the commonest single-gene cause of learning disability features in humans with an estimated prevalence of 1 in 4000- 1 in 6000 males, where it causes moderate to severe intellectual and social impairment together with syndromic features including large ears and head, long face and macroorchidism 1. A fragile site (FRAXA) is expressible at the gene locus at Xq27.3, typically in 2-40 % of blood cells in affected males. The pathogenic mutation in most cases is a large expansion (‘full mutation’) in a CGG repeat tract in the first untranslated exon of the gene FMR1, which normally encodes the RNA-binding protein FMRP. Full mutations (from approximately 200 repeats upwards) result in hypermethylation of the DNA in and around the CGG tract, curtailed gene expression and no FMRP being produced 2-4. Smaller expansions of the CGG repeat, or ‘premutations’ are not hypermethylated and hence do not cause Fragile X syndrome, but may show expansion into full mutations over one or more generations. -
What Is Multiple Myeloma?
cancer.org | 1.800.227.2345 About Multiple Myeloma Overview If you have been diagnosed with multiple myeloma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Multiple Myeloma? Research and Statistics See the latest estimates for new cases of multiple myeloma and deaths in the US and what research is currently being done. ● Key Statistics About Multiple Myeloma ● What’s New in Multiple Myeloma Research? What Is Multiple Myeloma? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also called immunoglobulins) that help the body attack and kill germs. Plasma cells, are found mainly in the bone marrow. -
ART and Miscarriage Risk Assoc
27-28 January, Sofia, Bulgaria ART and miscarriage risk Assoc. Prof. Petya Andreeva, MD, PhD D-r Shterev Hospital Dr. Shterev Sofia, BULGARIA HOSPITAL Dr. Shterev Miscarriage rate HOSPITAL 10 % to 15 % of clinical pregnancies have resulted in miscarriage. 1-2% miscarriages / per couples who try to conceive. (Macklon NS et al, 2002; Rai R et al 2006) Dr. Shterev Monthly fecundity rate (MFR) HOSPITAL In humans even in optimal circumstances – clinical recognized pregnancy in one cycle or the so called monthly fecundity rate is around 30 % . In contrast MFR is 80% in baboons and 90% in rabbits. (Chard T, 1991; . Foote RH 1988; Stevens VC 1997) Dr. Shterev Ongoing pregnancy rate HOSPITAL Assisted reproductive technologies (ART) represent average 30 % pregnancy rate. Around 50% of human conception fails implantation. Up to half of implanted embryos fail to progress in ongoing pregnancy. (Macklon N 2002; Macklon N 2014) Dr. Shterev Conception to ongoing pregnancy HOSPITAL Live births -True incidence of pregnancy loss is 30% closer to 50%. Miscarriage - This renders miscarriage as the 40-50% 10 % most common complication of pregnancy Early pregnancy loss 30 % Implantation failure 30 % CONCEPTION Macklon et al, Hum Reproduction Update, 2002 Dr. Shterev Known reasons for miscarriage HOSPITAL Antiphospholipid syndrome Endocrine abnormalities Thyroid dysfunction Diabetes Chromosome aberrations Uterine structural malformation Trombophilias Unknown factors in 50 % of cases. Dr. Shterev Embryo HOSPITAL The enormous rate of early pregnancy loss in humans thought to be as a consequences of two key features of human embryos: 1. High prevalence of chromosomal abnormalities. 2. Invasiveness. Dr. Shterev HOSPITAL -Good-quality cleavage-stage embryos exhibit high rates of aneuploidy. -
Biases Inherent in Studies of Coffee Consumption in Early Pregnancy and the Risks of Subsequent Events
nutrients Review Biases Inherent in Studies of Coffee Consumption in Early Pregnancy and the Risks of Subsequent Events Alan Leviton ID Boston Children’s Hospital and Harvard Medical School, 1731 Beacon Street, Brookline, MA 02445, USA; [email protected]; Tel.: +1-617-485-7187 Received: 24 July 2018; Accepted: 21 August 2018; Published: 23 August 2018 Abstract: Consumption of coffee by women early in their pregnancy has been viewed as potentially increasing the risk of miscarriage, low birth weight, and childhood leukemias. Many of these reports of epidemiologic studies have not acknowledged the potential biases inherent in studying the relationship between early-pregnancy-coffee consumption and subsequent events. I discuss five of these biases, recall bias, misclassification, residual confounding, reverse causation, and publication bias. Each might account for claims that attribute adversities to early-pregnancy-coffee consumption. To what extent these biases can be avoided remains to be determined. As a minimum, these biases need to be acknowledged wherever they might account for what is reported. Keywords: epidemiology; bias; causation; coffee; pregnancy 1. Introduction Maternal consumption of coffee during early pregnancy has been viewed as increasing the risk of miscarriage [1–4], fetal growth restriction [2,5–11], and childhood leukemias [12–20]. Unfortunately, many of the epidemiologic studies have not acknowledged the potential biases that appear to have influenced these perceptions of risk. The list of potential biases is long [21]. In this essay, I review five of these biases, namely recall bias, misclassification, residual confounding, reverse causation, and publication bias. Each of these biases might account for some of what has been reported. -
FDA Requests Removal of Strongest Warning Against Using Cholesterol
FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins Breastfeeding not recommended in patients who require statins 7-20-2021 FDA Drug Safety Communication What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant patients. Despite the change, most patients should stop statins once they learn they are pregnant. We have conducted a comprehensive review of all available data and are requesting that statin manufacturers make this change to the prescribing information as part of FDA’s ongoing effort to update the pregnancy and breastfeeding information for all prescription medicines. Patients should not breastfeed when taking a statin because the medicine may pass into breast milk and pose a risk to the baby. Many can stop statins temporarily until breastfeeding ends. However, patients requiring ongoing statin treatment should not breastfeed and instead use infant formula or other alternatives. What is FDA doing? We are requesting revisions to the information about use in pregnancy in the prescribing information of the entire class of statin medicines. These changes include removing the contraindication against using these medicines in all pregnant patients. A contraindication is FDA’s strongest warning and is only added when a medicine should not be used because the risk clearly outweighs any possible benefit. Because the benefits of statins may include prevention of serious or potentially fatal events in a small group of very high-risk pregnant patients, contraindicating these drugs in all pregnant women is not appropriate. -
Maternal Age, History of Miscarriage, and Embryonic/Fetal Size Are Associated with Cytogenetic Results of Spontaneous Early Miscarriages
Journal of Assisted Reproduction and Genetics (2019) 36:749–757 https://doi.org/10.1007/s10815-019-01415-y GENETICS Maternal age, history of miscarriage, and embryonic/fetal size are associated with cytogenetic results of spontaneous early miscarriages Nobuaki Ozawa1 & Kohei Ogawa1 & Aiko Sasaki1 & Mari Mitsui1 & Seiji Wada1 & Haruhiko Sago1 Received: 1 October 2018 /Accepted: 28 January 2019 /Published online: 9 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose To clarify the associations of the maternal age, history of miscarriage, and embryonic/fetal size at miscarriage with the frequencies and profiles of cytogenetic abnormalities detected in spontaneous early miscarriages. Methods Miscarriages before 12 weeks of gestation, whose karyotypes were evaluated by G-banding between May 1, 2005, and May 31, 2017, were included in this study. The relationships between their karyotypes and clinical findings were assessed using trend or chi-square/Fisher’s exact tests and multivariate logistic analyses. Results Three hundred of 364 miscarriage specimens (82.4%) had abnormal karyotypes. An older maternal age was significantly associated with the frequency of abnormal karyotype (ptrend < 0.001), particularly autosomal non-viable and viable trisomies (ptrend 0.001 and 0.025, respectively). Women with ≥ 2 previous miscarriages had a significantly lower possibility of miscarriages with abnormal karyotype than women with < 2 previous miscarriages (adjusted odds ratio [aOR], 0.48; 95% confidence interval [95% CI], 0.27–0.85). Although viable trisomy was observed more frequently in proportion to the increase in embryonic/fetal size at miscarriage (ptrend < 0.001), non-viable trisomy was observed more frequently in miscarriages with an embryonic/fetal size < 10 mm (aOR, 2.41; 95% CI, 1.27–4.58), but less frequently in miscarriages with an embryonic/fetal size ≥ 20 mm (aOR, 0.01; 95% CI, 0.00–0.07) than in anembryonic miscarriages. -
Lymphoproliferative Disorders
Lymphoproliferative disorders Objectives: • To understand the general features of lymphoproliferative disorders (LPD) • To understand some benign causes of LPD such as infectious mononucleosis • To understand the general classification of malignant LPD Important. • To understand the clinicopathological features of chronic lymphoid leukemia Extra. • To understand the general features of the most common Notes (LPD) (Burkitt lymphoma, Follicular • lymphoma, multiple myeloma and Hodgkin lymphoma). Success is the result of perfection, hard work, learning Powellfrom failure, loyalty, and persistence. Colin References: Editing file 435 teamwork slides 6 girls & boys slides Do you have any suggestions? Please contact us! @haematology436 E-mail: [email protected] or simply use this form Definitions Lymphoma (20min) Lymphoproliferative disorders: Several clinical conditions in which lymphocytes are produced in excessive quantities (Lymphocytosis) increase in lymphocytes that are not normal Lymphoma: Malignant lymphoid mass involving the lymphoid tissues. (± other tissues e.g: skin, GIT, CNS ..) The main deference between Lymphoma & Leukemia is that the Lymphoma proliferate primarily in Lymphoid Tissue and cause Mass , While Leukemia proliferate mainly in BM& Peripheral blood Lymphoid leukemia: Malignant proliferation of lymphoid cells in Bone marrow and peripheral blood. (± other tissues e.g: lymph nodes, spleen, skin, GIT, CNS ..) BCL is an anti-apoptotic (prevent apoptosis) Lymphocytosis (causes) 1- Viral infection: 2- Some* bacterial